Italy has great capacity for innovation, which will also bear fruit in the fight against Covid.
This was stated during a forum at ANSA by Elcin Barker Ergun, CEO of the Menarini group, who arrived at the helm of the company for a year after an experience of several years in Boston.
"I was really impressed by the Italian capabilities in terms of innovation and science - she said - and among other things, this is how we managed to bring the antibodies to Italy and beyond. It paid off thanks to the incredible capabilities accumulated in the years in the valley of Siena and therefore I believe that Italy is no less in terms of capacity than other parts of the world ".
By 2021, the Menarini group could provide patients with monoclonal antibodies against the Sars-Cov-2 virus.
"We have a production chain for oncological therapies in which monoclonal antibodies play an important role and the production, the process and the technology behind it have been developed by us, in our biotechnology plant in Pomezia - remembers Barker Ergun. -. We have entered into a partnership with Tuscany Life Sciences (TLS). The antibodies come from Italian hospitals and in practice are processed to perform the first experiments that will eventually be transferred to us, in our facilities with cloning technologies, where we will produce the clinical trial material.
The plan is to go very fast in carrying out clinical trials, early next year, to deliver them to patients as quickly as possible, by 2021 ".
